hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06373224, orgStudyIdInfo id: 23-037, briefTitle: Cold Saline Irrigation Before Endobronchial Biopsy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-12-02, completionDateStruct date: 2025-02-02, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: TriHealth Inc., class: OTHER, descriptionModule briefSummary: Patients undergoing an endobronchial ultrasound and biopsy can experience bleeding during the biopsy. These biopsies are read in real time by pathologists who travel to the endoscopy unit during the procedure. Often, when this happens, the blood contaminates the pathology slides making the slide unreadable. This then requires more biopsies to be performed, thus prolonging the procedure, and increasing anesthesia time. One innovative way to reduce bleeding may be to irrigate the bronchial wall with cold saline, where the biopsy is to be taken, immediately before biopsy, thus causing vasoconstriction and possibly resulting in less blood contamination on the biopsy slides. The current study will evaluate this prophylactic irrigation with saline to control bleeding, thus resulting in a quicker diagnostic result of the biopsies., conditionsModule conditions: Lung Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Flush, outcomesModule primaryOutcomes measure: Incidence of unreadable biopsy slides, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bethesda North Hospital, status: RECRUITING, city: Cincinnati, state: Ohio, zip: 45242, country: United States, contacts name: Rachel Baker, PhD, RN, role: CONTACT, phone: 513-569-6191, email: Rachel_Baker2@trihealth.com, geoPoint lat: 39.12713, lon: -84.51435, hasResults: False
protocolSection identificationModule nctId: NCT06373185, orgStudyIdInfo id: 2023/21, briefTitle: Comparison of the Efficacy of Sacral Espb and Caudal Block for Pain Management After Urogenital Surgeries in Children, acronym: SESPB, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Giresun University, class: OTHER, descriptionModule briefSummary: The aim of this study was to compare the efficacy of caudal block and sacral espb used as a postoperative analgesia method in urogenital pediatric surgery cases., conditionsModule conditions: Urogenital Diseases, conditions: Nerve Block, conditions: Pain, Postoperative, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized controlled double blind study, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Randomisation using a closed envelope method based on computer-generated random numbers was to assign patients to two equal groups. Group 1 received midline US-guided sacral erector spinae plane block and Group 2 received caudal block. The experienced anesthetist who opened the envelope performed the block according to the group code and patients were followed postoperatively by an anesthetist blinded to which block was performed. Patients were also blinded as to which block was performed., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-guided sacral erector spinae plane block, interventions name: Ultrasound-guided caudal block, outcomesModule primaryOutcomes measure: Face, Leg, Activity, Cry, Consolability (FLACC) score, secondaryOutcomes measure: Analgesic requirement, secondaryOutcomes measure: Satisfaction of the patient's parents, secondaryOutcomes measure: Satisfaction of the surgeons, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 7 Years, stdAges: CHILD, contactsLocationsModule locations facility: Giresun Research and Training Hospital, status: RECRUITING, city: Gi̇resun, state: Central, zip: 28100, country: Turkey, contacts name: Bilge Olgun Keleş, role: CONTACT, phone: 05317338805, email: bilge.olgun@hotmail.com, contacts name: Dilek Yeniay, role: CONTACT, phone: 05375521553, email: dilekyeniay@hotmail.com, geoPoint lat: 40.91698, lon: 38.38741, hasResults: False
protocolSection identificationModule nctId: NCT06373172, orgStudyIdInfo id: 202005-HR-003, briefTitle: Enhancing Clinical Reasoning Competency, acronym: Reasoning, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-05-01, primaryCompletionDateStruct date: 2020-06-01, completionDateStruct date: 2023-03-01, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Tongmyong University, class: OTHER, descriptionModule briefSummary: Enhancing Clinical Reasoning Competency for Undergraduate Nursing Students Using Virtual Simulation-based Education based on the Rasch modelAims: Clinical reasoning is a core nursing competency that involves analyzing patient-related data and providing appropriate nursing practices. Simulation-based education is effective in improving the clinical reasoning competencies and communication skills of nursing students. This study aimed to verify the effectiveness of virtual simulation-based education., conditionsModule conditions: Clinical Reasoning, conditions: Communication, conditions: Development, Human, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: This quasi-experimental study used a single-group pretest-posttest design to verify the effectiveness of virtual simulation-based education for undergraduate nursing students., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 37, type: ACTUAL, armsInterventionsModule interventions name: virtual simulation-based education program, outcomesModule primaryOutcomes measure: Nurses Clinical Reasoning Scale, primaryOutcomes measure: Communication Skills Scale, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 28 Years, stdAges: ADULT, contactsLocationsModule locations facility: Tongmyong Unoversity, city: Busan, zip: 48520, country: Korea, Republic of, geoPoint lat: 35.10278, lon: 129.04028, hasResults: False
protocolSection identificationModule nctId: NCT06373133, orgStudyIdInfo id: 2024 (82), briefTitle: SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-11-01, completionDateStruct date: 2026-11-01, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: West China Hospital, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer., conditionsModule conditions: Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: SHR-8068, interventions name: Adebrelimab, interventions name: BP102, outcomesModule primaryOutcomes measure: Dose-limiting toxicity, primaryOutcomes measure: PFS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06373107, orgStudyIdInfo id: 2117651-2, briefTitle: Investigating Effects of High-intensity Gait Training on Gait, Balance and Depression Post-stroke, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-11, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2026-01-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Alvernia University, class: OTHER, collaborators name: Lehigh Valley Health Network, descriptionModule briefSummary: The purpose of this research is to study the improvements from walking practice that is vigorous enough to keep participants' heart rate over a certain target level during their physical therapy sessions. The investigators want to know about improvements in participants' walking function and mental health after 20 interventions. The study also aims to evaluate if participants' mental health, social support, and health literacy affect their attendance at physical therapy sessions., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: High intensity gait training, outcomesModule primaryOutcomes measure: 3-meter backwards walk test, primaryOutcomes measure: 6-minute walk test, primaryOutcomes measure: 10-meter walk test, primaryOutcomes measure: Surface electromyography (EMG), primaryOutcomes measure: Berg Balance Scale, primaryOutcomes measure: Functional Gait Assessment, primaryOutcomes measure: Borg Rating Scale of Perceived Exertion (RPE), primaryOutcomes measure: Patient Health Questionnaire (PHQ-9), primaryOutcomes measure: Rate of patient attendance (Compliance) to physical therapy, primaryOutcomes measure: Newest Vital Sign, primaryOutcomes measure: Multidimensional Scale of Perceived Social Support (MSPSS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lehigh Valley Health Network Outpatient Neurologic Rehab, city: Allentown, state: Pennsylvania, zip: 18104-2310, country: United States, contacts name: Sandra M Tremblay, DPT, role: CONTACT, geoPoint lat: 40.60843, lon: -75.49018, hasResults: False
protocolSection identificationModule nctId: NCT06373094, orgStudyIdInfo id: DON102-CTP, briefTitle: A Single Dose Escalation Study of HHT201 in Healthy Subjects, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Shanghai Synergy Pharmaceutical Sciences Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects., conditionsModule conditions: Alzheimer Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Donepezil Dihydroxynaphthalate for Injection, outcomesModule primaryOutcomes measure: Adverse events, primaryOutcomes measure: Number of Participants With Abnormal Laboratory Values, primaryOutcomes measure: Number of Participants With Abnormal ECG QT Interval, primaryOutcomes measure: Number of Participants With Abnormal Vital signs, primaryOutcomes measure: Number of Participants With Abnormal Physical examination, primaryOutcomes measure: VAS, secondaryOutcomes measure: Cmax of Donepezil, secondaryOutcomes measure: Tmax of Donepezil, secondaryOutcomes measure: AUC0-t of Donepezil, secondaryOutcomes measure: AUC0-∞ of Donepezil, secondaryOutcomes measure: t1/2z of Donepezil, secondaryOutcomes measure: Vz/F, secondaryOutcomes measure: CLz/F, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 59 Years, stdAges: ADULT, contactsLocationsModule locations facility: Zhejiang Province Taizhou Hospital Luqiao Hospital (Enze Hospital) (Taizhou Hospital Phase I Center), city: Taizhou, state: Zhe Jiang, zip: 318000, country: China, contacts name: Donqing Lv, role: CONTACT, phone: 86-0576-85199816, email: lvdq@enzemed.com, contacts name: Zhanrong Ye, role: CONTACT, phone: 86-0576-85199816, email: Zoe.Ye@enzemed-crc.com, geoPoint lat: 32.49069, lon: 119.90812, hasResults: False
protocolSection identificationModule nctId: NCT06373081, orgStudyIdInfo id: CD19-CD3E-CN-A1, briefTitle: Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2025-04-15, completionDateStruct date: 2026-04-15, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Shanghai Changzheng Hospital, class: OTHER, descriptionModule briefSummary: This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases., conditionsModule conditions: Systemic Lupus Erythematosus (SLE), conditions: Sjogren's Syndrome, conditions: Systemic Sclerosis, conditions: Inflammatory Myopathy, conditions: ANCA Associated Vasculitis, conditions: Antiphospholipid Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 6, type: ESTIMATED, armsInterventionsModule interventions name: Anti-CD19-CD3E-CAR-T cells, outcomesModule primaryOutcomes measure: The incidence of dose-limiting toxicities (DLTs) (Safety), primaryOutcomes measure: Proportion of patients for whom the desired dose of anti-CD19-CD3E-CAR-T cells can be successfully manufactured, primaryOutcomes measure: Clinical response for relapsed/Refractory SLE, primaryOutcomes measure: Clinical response for Sjögren's Syndrome, primaryOutcomes measure: Clinical response for relapsed/refractory/progressive systemic sclerosis, primaryOutcomes measure: Clinical response for relapsed/refractory/progressive inflammatory myopathy, primaryOutcomes measure: Clinical response for relapsed/refractory anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis:, primaryOutcomes measure: Clinical response for relapsed/refractory/Catastrophic Antiphospholipid Syndrome, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai ChangZheng hospital, status: RECRUITING, city: Shanghai, zip: 200003, country: China, contacts name: Huji Xu, role: CONTACT, phone: 86021-81885514, email: xuhuji@smmu.edu.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06373068, orgStudyIdInfo id: Resuscitation Orders ICU, briefTitle: Association Between Resuscitation Orders and Mortality in ICU Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, descriptionModule briefSummary: The hypothesis of the study is that a resuscitation order other than full code is associated with increased mortality among critically ill patients. By incorporating conventional variables associated with death such as age, sex, and Simplified Acute Physiological Score, as well as including the new Clinical Frailty Scale in a statistical model, the aim is to investigate whether there is still an increased risk of death that remains unexplained., conditionsModule conditions: Critical Illness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1500, type: ESTIMATED, armsInterventionsModule interventions name: Resuscitation orders, outcomesModule primaryOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 16 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06373055, orgStudyIdInfo id: 4-2023-1232, briefTitle: Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2033-11, completionDateStruct date: 2033-11, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Yonsei University, class: OTHER, descriptionModule briefSummary: Although neoadjuvant chemotherapy in muscle-invasive bladder cancer has significantly improved oncological outcomes, approximately 50% of patients do not respond to neoadjuvant chemotherapy, which has adverse effects on patients by causing treatment toxicity and surgical delays. Therefore, treatment tailored specifically to the individual patient based on the genetic and/or molecular profile of the patient is urgently needed. Among patients scheduled for neoadjuvant chemotherapy, the investigators should differentiate between patients who will be highly effective with neoadjuvant chemotherapy and those who will not, and preferentially select other treatments including radical cystectomy in the patients with high probability of failure to neoadjuvant chemotherapy. However, there is no standard which patients would benefit from neoadjuvant chemotherapy. This study plans to predict treatment response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer by analyzing genetic and molecular profiles of tumor tissues obtained through transurethral bladder tumor resection., conditionsModule conditions: Muscle-invasive Bladder Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: neoadjuvant chemotherapy followed by radical cystectomy, outcomesModule primaryOutcomes measure: Identification of responder to neoadjuvant chemotherapy by genetic and molecular profiles, secondaryOutcomes measure: overall survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy, secondaryOutcomes measure: cancer-specific survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy, secondaryOutcomes measure: progression-free survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy, secondaryOutcomes measure: recurrence-free survival of bladder cancer patients who have undergone neoadjuvant chemotherapy and radical cystectomy, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Won Sik Ham, role: CONTACT, phone: 02-2228-2310, email: uroham@yuhs.ac, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06373029, orgStudyIdInfo id: 2023PHB211-001(2), briefTitle: Deep-learning Enabled Ultrasound Diagnosis of Anterior Talofibular Ligament Injury, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2024-05-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Peking University People's Hospital, class: OTHER, descriptionModule briefSummary: Ultrasound (US) is a more cost-effective, accessible, and available imaging technique to assess anterior talofibular ligament (ATFL) injuries compared with magnetic resonance imaging (MRI). However, challenges in using this technique and increasing demand on qualified musculoskeletal (MSK) radiologists delay the diagnosis. The investigators have already developed a deep convolutional network (DCNN) model that automates detailed classification of ATFL injuries. The investigators hope to use the DCNN in real-world clinical setting to test its diagnostic accuracy., conditionsModule conditions: Ultrasound, conditions: Anterior Talofibular Ligament, conditions: Deep Learning, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound examination, outcomesModule primaryOutcomes measure: classification of ATFL injury, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University People's Hospital, city: Beijing, state: Beijing, zip: 100032, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06373003, orgStudyIdInfo id: SNAPSITA, briefTitle: Negative Antiphospholipid Syndrome: a Multicentric Study, acronym: SNAPSITA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-04-18, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Italian Society for Rheumatology, class: OTHER, descriptionModule briefSummary: Multicentre no-profit, national, (cross-sectional diagnostic) retrospective study, promoted by the Italian Society for Rheumatology.The main objective of the study is to assess the diagnostic accuracy of non-criteria aPL (anti-vimentin/cardiolipin and anti-phosphatidylserine/prothrombin) in identifying APS in patients with thrombosis/recurrent adverse pregnancy outcomes.The recruited patients have the following criteria:(i)Patients fulfilling the classification criteria for antiphospholipid syndrome (seropositive APS, SP-APS) or patients with seronegative APS (SN-APS) or patients with clinical criteria (thrombotic or obstetric) for APS, negative for aPL, but without clinical features highly suggestive of APS; (ii) Age \<65 years; (iii) less than 5 years from the first event to the beginning of the study., conditionsModule conditions: Antiphospholipid Syndrome, conditions: Seronegative Antiphospholipid Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 105, type: ESTIMATED, armsInterventionsModule interventions name: Diagnostic accuracy, outcomesModule primaryOutcomes measure: Primary endpoint, secondaryOutcomes measure: Secondary endpoint_1, secondaryOutcomes measure: Secondary endpoint_2, secondaryOutcomes measure: Secondary endpoint_3, otherOutcomes measure: Exploratory Endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UOC di Reumatologia - AOU Policlinico Umberto I, "Sapienza" Università di Roma, status: RECRUITING, city: Roma, state: Rome, zip: 00185, country: Italy, contacts name: Simona Truglia, MD, role: CONTACT, phone: 06 49974631, email: simona.truglia@uniroma1.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False